“…As a first example from Neurology, Soldovieri et al are working on personalized options for patients with KCNMA1‐linked channelopathies 5 . Other focus areas are acute and chronic kidney diseases: Cantow et al recently established noninvasive monitoring of kidney size to assess changes in renal oxygenation, 6 while Kresse et al have characterized the EP1 receptor as s high‐potential target for preventing renal fibrosis, findings which may, in a timely manner, translate to clinical care 7 . Lichtenberger and Patzak, 8 as well as Sholokh and Klussmann, 9 in recent publications, provide systematic overviews of recent findings published in Acta Physiologica, which hold the potential to shift the therapy of acute 8 and chronic 9 kidney injury, respectively, from a symptomatic to a causal approach.…”